Compared to Estimates, Colgate-Palmolive (CL) Q3 Earnings: A Look at Key Metrics

Core Insights - Colgate-Palmolive reported revenue of $5.03 billion for Q3 2024, a year-over-year increase of 2.4% and a surprise of +0.48% over the Zacks Consensus Estimate of $5.01 billion [1] - The company's EPS for the quarter was $0.91, compared to $0.86 a year ago, resulting in an EPS surprise of +3.41% against the consensus estimate of $0.88 [1] Revenue Performance by Region - North America: Net Sales of $1 billion, exceeding the estimate of $998.89 million, with a year-over-year change of +1.4% [1] - Latin America: Net Sales of $1.16 billion, slightly below the estimate of $1.19 billion, reflecting a year-over-year decline of -3.2% [1] - Africa/Eurasia: Net Sales of $278 million, surpassing the estimate of $266.72 million, with a year-over-year increase of +4.5% [1] - Europe: Net Sales of $744 million, close to the estimate of $748.33 million, showing a year-over-year change of +2.6% [1] - Asia Pacific: Net Sales of $725 million, exceeding the estimate of $701.56 million, with a year-over-year increase of +6.3% [1] - Pet Nutrition: Net Sales of $1.13 billion, above the estimate of $1.10 billion, reflecting a year-over-year increase of +6.4% [1] - Total Oral, Personal and Home Care: Net Sales of $3.91 billion, matching the average estimate, with a year-over-year change of +1.3% [1] Profitability Metrics - Total Oral, Personal and Home Care Operating Profit: $1.02 billion, below the estimate of $1.07 billion [1] - Corporate Operating Profit: -$208 million, compared to the average estimate of -$199.14 million [1] - Pet Nutrition Operating Profit: $258 million, exceeding the estimate of $217.20 million [1] Stock Performance - Colgate-Palmolive shares have returned -3.2% over the past month, while the Zacks S&P 500 composite has changed by +1.4% [2] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [2]